Clinical trials: COVID19 ARDS
Respiratory Distress Syndrome, Adult
COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 22.
- Trial name
- NCT04388826
- Testing
- Veru-111
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Veru Inc.
Acute Respiratory Distress Syndrom (SARS-Cov 2)
Evaluation of the Prognostic Value of T7 and T12 Slices on Mortality in Resuscitation Patients With ARDS Caused by SARS-COV2 Infection
Sarcopenia is a risk factor for adverse outcome in critically ill patients. Sarcopenia might be estimated from muscle surface measure on tomodensitometry.
- Trial name
- MUSCOV (NCT05594550)
- Testing
- Data collection, analysis of thoracic scans
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Pneumonia
Cerebral Autoregulation and COVID-19
This study aims to assess cerebral autoregulation by near-infrared spectroscopy (NIRS) in patients with severe coronavirus disease 19 (COVID-19).
- Trial name
- CA-COVID (NCT04930874)
- Testing
- NIRS (Near-Infrared Spectroscopy)
- Where
- Greece
- Volunteers
- 7 people
- Sponsor
- University of Athens
COVID-19, SARS-CoV2
Host Response Mediators in Coronavirus (COVID-19) Infection
The coronavirus (COVID-19) pandemic continues to grow exponentially. Angiotensin II levels are increased in human influenza and are associated with influenza viral load, disease progression and mortality.
- Trial name
- ARBS CORONA I (NCT04510623)
- Testing
- ARBs and/or ACE inhibitors, Usual Care
- Where
- 15 sites in Canada
- Volunteers
- 500 people
- Sponsor
- University of British Columbia
ARDS Due to COVID-19
Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19
The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.
- Trial name
- NCT04568018
- Testing
- Surfactant
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biosurf LLC.
Respiratory Distress Syndrome
Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19
Describe COVID-19 patients who are receiving ECMO-VV respiratory replacement and what happens to them.
- Trial name
- ECMO-COVID-19 (NCT04343404)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
ARDS, COVID
Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique
COVID 19 is a novel and severe disease. One of the problems is that the virus disturbs the lungs and cause water accumulation in lungs alveolus (ARDS).
- Trial name
- NCT04406493
- Testing
- Lung impedance technique
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hillel Yaffe Medical Center
SARS-CoV Infection
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
- Trial name
- VERU-111 (NCT04842747)
- Testing
- VERU-111
- Where
- 58 sites in United States, Argentina and 4 more
- Volunteers
- 204 people
- Sponsor
- Veru Inc.
SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome
Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease
Background:The impact of the emergence of SARS-CoV-2 variants on the severity and clinical outcomes of COVID-19 is controversial.
- Conditions
- SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome, Mutation
- Trial name
- SEVARVIR (NCT05162508)
- Testing
- Nasopharyngeal swab
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Respiratory Distress Syndrome, COVID-19
Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.
- Trial name
- NCT04402840
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- West Virginia University
Severe to Critical COVID 19 With Associated ARDS
A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19
This is a Phase 2/3, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of FP-025 in adult patients with severe to critical COVID 19 with associated ARDS.
- Trial name
- NCT04750278
- Testing
- FP-025 100 mg, FP-025 300 mg
- Where
- 8 sites in United States
- Volunteers
- 90 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Covid-19, ARDS
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including…
- Conditions
- Covid-19, ARDS, Pneumonia
- Trial name
- NCT04365764
- Where
- 2 sites in France
- Volunteers
- 400 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Muscular Diseases, COVID-19 Acute Respiratory Distress Syndrome
Ultrasound Grayscale Analysis in ARDS covid19
Recent evidence regarding the novel coronavirus disease 2019 (COVID19) is growing in describing the characteristics of this disease, with main focus on lung morphology.
- Trial name
- Graycovid (NCT04863534)
- Testing
- Ultrasound
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- University of Milan
COVID-19 Pneumonia, COVID-19
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in…
- Conditions
- COVID-19 Pneumonia, COVID-19, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05164744
- Testing
- Cardiac MRI, Echocardiogram, 6-minute walk test
- Where
- 3 sites in United States
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
COVID-19, SARS-CoV 2
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort
DESIGN Longitudinal prospective observational multicentre study. Primary objective: Understand the immune mechanisms driving COVID-19 disease in patients with a history of lung disease
- Conditions
- COVID-19, SARS-CoV 2, ARDS, Human, Immune System Disorder
- Trial name
- PROSAIC-19 (NCT04444609)
- Testing
- Blood tests sputum, nasal lavage and brushing
- Where
- United Kingdom
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Critically Illness, Sedation
Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)
The authors hypothesized that inhaled sedation, either with isoflurane or sevoflurane, might be associated with improved clinical outcomes in patients with COVID-19-related ARDS, compared to intravenous sedation.
- Conditions
- Critically Illness, Sedation, Invasive Mechanical Ventilation, Acute Respiratory Distress Syndrome
- Trial name
- ISCA (NCT04383730)
- Testing
- Intravenous sedation, Inhaled sedation
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 203 people
- Sponsor
- University Hospital, Clermont-Ferrand
Acute Respiratory Distress Syndrome, Ards
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
This is a Phase 2 randomized study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for subjects hospitalized subjects with acute respiratory distress syndrome not related to…
- Trial name
- NCT04909879
- Testing
- COVI-MSC
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19 Pneumonia, Covid19
A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19
The aim of the study is to investigate the role of SB 8.4% as adjuvant therapy in the treatment of COVID- 19 patients proved to be RT-PCR positive (mild, moderate and severe).
- Conditions
- COVID-19 Pneumonia, Covid19, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05035524
- Testing
- Sodium Bicarbonate Solution
- Where
- Egypt
- Volunteers
- 340 people
- Sponsor
- Mansoura University
Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Efficacy and Safety of Itolizumab in COVID-19 Complications
Randomized, Parallel Group, Active Controlled Trial
- Conditions
- Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19
- Trial name
- NCT04475588
- Testing
- Itolizumab IV infusion, Best supportive care (BSC)
- Where
- 4 sites in India
- Volunteers
- 32 people
- Sponsor
- Biocon Limited
Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection
An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications
This observational study will collect data from patients treated with siltuximab program for treatment of SARS-CoV-2 infection complicated with serious respiratory complications.
- Trial name
- SISCO (NCT04322188)
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII